IL13Rα2-targeted CD4+ CAR-T cells

IL13Rα2-targeted CD4+ CAR-T cells are an investigational adoptive cell therapy consisting of autologous or donor-derived CD4+ T lymphocytes engineered to express a second-generation chimeric antigen receptor (CAR) targeting the interleukin-13 receptor alpha 2 (IL13Rα2). IL13Rα2 is a tumor-associated antigen frequently overexpressed in glioblastoma multiforme (GBM) but with limited expression in normal brain tissue. While most CAR-T therapies utilize a mixture of CD4+ and CD8+ cells or focus on CD8+ effector cells, research led by City of Hope has demonstrated that the CD4+ subset exhibits superior persistence and sustained effector potency against GBM, resisting exhaustion better than CD8+ cells. The therapy is typically administered intracranially (intratumoral or intraventricular) to bypass the blood-brain barrier and maximize local effector function.

Other names

IL13Rα2-specific CD4+ CAR-T cellsCD4+ IL13Rα2-CAR T cells